Structure Therapeutics (GPCR) Current Assets (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Current Assets of $1.5 billion for Q1 2026, up 75.44% year-over-year from $849.6 million in Q1 2025, and down 5.08% quarter-over-quarter from $1.6 billion in Q4 2025.
Structure Therapeutics (GPCR) Current Assets (2022 - 2026) Analysis & Trends
Structure Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Current Assets rose 75.44% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 75.44% YoY), while the FY2025 annual figure was $1.6 billion, up 76.2% from the prior year.
- Current Assets for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
- The five-year high for Current Assets was $1.6 billion in Q4 2025, with the low at $93.1 million in Q4 2022.
- The 5-year median for Current Assets is $806.7 million (2025), against an average of $712.6 million.
- The sharpest annual moves came in 2023 and 2025: Current Assets soared 408.77% in 2023, then dropped 14.75% in 2025.
- Structure Therapeutics' Current Assets stood at $93.1 million in 2022, then jumped by 408.77% to $473.6 million in 2023, then jumped by 88.17% to $891.2 million in 2024, then jumped by 76.2% to $1.6 billion in 2025, then slipped by 5.08% to $1.5 billion in 2026.
- Business Quant data shows GPCR's Current Assets at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $814.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Bn |
| Mar 31, 2026 | 1.49 Bn |
| Dec 31, 2025 | 1.57 Bn |
| Sep 30, 2025 | 814.02 Mn |
| Jun 30, 2025 | 799.30 Mn |
| Mar 31, 2025 | 849.62 Mn |
| Dec 31, 2024 | 891.21 Mn |
| Sep 30, 2024 | 923.65 Mn |
| Jun 30, 2024 | 937.62 Mn |
| Mar 31, 2024 | 449.36 Mn |
| Dec 31, 2023 | 473.61 Mn |
| Sep 30, 2023 | 209.96 Mn |
| Jun 30, 2023 | 228.22 Mn |
| Mar 31, 2023 | 246.16 Mn |
| Dec 31, 2022 | 93.09 Mn |